Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Peds Proton Therapy

13 novembre 2026 aggiornato da: University of Wisconsin, Madison

Operational and Clinical Evaluation of the Treatment Planning Software and Oncology Information System for Pediatric Proton Therapy

This study is being done to evaluate the clinical utilization and safety of RayStation 2025 and RayCare 2025 treatment planning software upgrades when used to support standard-of-care proton therapy delivery in patients deemed clinically appropriate for such therapy by their treating radiation oncologist.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

In this study, the radiation treatment itself, including target definitions, prescription dose, treatment delivery, verification imaging, and adaptive treatment planning, is standard of care.

Current standard radiation therapy planning is based on a treatment plan generated from a planning computed tomography (CT) scan obtained before treatment begins. This plan is generally used for the entire course of therapy, with verification imaging performed during treatment primarily used to verify patient positioning rather than to recalculate delivered dose. On occasion, it is standard practice for a physician to determine, based on his or her interpretation of verification imaging, that an adaptive replanning of the treatment is needed to account for anatomic changes that the physician observes on verification imaging which mandate a change to the plan. Comprehensive software-based evaluation of the cumulative dose delivered over multiple fractions is not routinely performed in most clinical settings. Performing such evaluations typically requires manual steps including image registration, dose recalculation on additional imaging datasets, deformable dose mapping, and manual accumulation of dose across fractions. With currently FDA-approved tools for proton therapy treatment plan evaluation, these processes are time-consuming and require significant physics and physician resources. As a result, detailed adaptive dose evaluation is usually performed only in selected cases or as a one-time assessment during a treatment course, rather than as a routine component of daily clinical care.

The investigational component involves the prospective evaluation of the RayAdaptive and RayTracker software tools to assess their performance, reliability, usability, and clinical feasibility. These software features are not currently available for routine clinical use, being not yet FDA-cleared, in the configuration evaluated in this protocol and are being assessed in a defined prospective clinical research setting.

This is a nonrandomized, single arm, open-label, prospective interventional trial to determine the rate of adaptive replanning for proton therapy when RayTracker and RayAdaptive are used as decision-support tools in the analysis of every verification image obtained during each participant's proton therapy treatment course. This study will evaluate, under a defined prospective clinical research framework, the performance, reliability, usability, and clinical feasibility of implementing RayTracker and RayAdaptive - software components that have not yet been 510(k) cleared by the U.S. Food and Drug Administration (FDA).

Primary Objective

• To determine the frequency of adaptive replanning during proton therapy when RayTracker and RayAdaptive are incorporated into routine verification image review as clinical decision-support tools.

Secondary Objectives

  • To evaluate the treating physician-reported rate at which RayTracker and RayAdaptive influenced the decision to pursue adaptive replanning during proton therapy.
  • To explore concordance between RayAdaptive-predicted inadequate target coverage on verification imaging and findings on repeat CT simulation when performed.
  • To explore concordance between RayAdaptive-predicted organ-at-risk dose constraint violations and findings on repeat CT simulation when performed.
  • To report the incidence of adverse events (AEs) and device deficiencies related to the investigational RayTracker/RayAdaptive software.

Tipo di studio

Interventistico

Iscrizione (Stimato)

80

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53792
        • Reclutamento
        • University of Wisconsin

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Non più vecchio di 17 anni (Bambino)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age less than or equal to 17 years at the time of consent/assent.
  • Patient has a clinical indication for radiation therapy, and the treating radiation oncologist has independently determined that proton therapy is clinically appropriate and has recommended proton therapy as part of the patient's routine clinical care, independent of participation in this research study. Proton therapy may be delivered with or without anesthesia when clinically indicated.
  • Written informed consent will be obtained from adult subjects or the parent/legal guardian of pediatric subjects. Assent will be obtained from pediatric participants when appropriate according to institutional policy.

Exclusion Criteria:

  • Patient has contraindications to proton therapy (per standard clinical guidelines).
  • Patient is unable to comply with routine treatment workflow or follow-up.
  • Patients who will be treated with a radiation plan of 5 fractions or fewer.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Standard of Care Proton Therapy

Part of a not yet FDA-cleared software, the RaySearch treatment planning system and RayCare oncology information system. RayTracker enables longitudinal evaluation of treatment by recalculating dose on daily images and accumulating dose across fractions using deformable image registration, thereby providing an estimate of the cumulative delivered dose to targets and organs at risk. RayAdaptive uses daily treatment imaging (such as cone-beam CT (CBCT)) together with the planning CT to generate an updated representation of patient anatomy and recalculation of dose on the current patient anatomy, allowing clinicians to evaluate whether anatomical changes could meaningfully alter the planned dose distribution. These features are designed to be used in tandem. Their combined capabilities are intended to support clinical decision-making related to treatment monitoring and potential adaptation.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of verification image assessments for each subject resulting in a clinical adaptive replanning decision
Lasso di tempo: up to 6 months

Defined as ordering repeat CT simulation and/or treatment plan reoptimization.

up to 6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Treating physician-reported influence of RayTracker/RayAdaptive on adaptive replanning decisions
Lasso di tempo: up to 6 months

Can I define this outcome to be: Did the RayTracker / RayAdaptive intervention influence your clinical decision? [Yes / No] This will be reported by physician count.

up to 6 months
Concordance between RayAdaptive predictions of inadequate target coverage and findings on repeat CT simulation
Lasso di tempo: up to 6 months
up to 6 months
Concordance between RayAdaptive predictions of organ-at-risk dose constraint violations and findings on repeat CT simulation
Lasso di tempo: up to 6 months
up to 6 months
Incidence of AEs and device deficiencies
Lasso di tempo: up to 6 months

Incidence of AEs and device deficiencies at least possibly related to use of the investigational RayTracker/RayAdaptive software or its incorporation into the clinical workflow as assessed throughout the course of proton therapy and for 90 days following completion of proton treatment. Device deficiencies may include software malfunction, calculation error, deformable registration failure, software defect, or software limitations affecting treatment plan evaluation, image review, or data analysis.

up to 6 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Brett Morris, MD, PhD, UW School of Medicine and Public Health

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 ottobre 2026

Completamento primario (Stimato)

1 gennaio 2029

Completamento dello studio (Stimato)

1 gennaio 2029

Date di iscrizione allo studio

Primo inviato

13 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2026-1312
  • Protocol Version 7/26/26 (Altro identificatore: UW Madison)
  • SMPH | Radiation Medicine (Altro identificatore: UW Madison)
  • UW26111 (Altro identificatore: OnCore ID)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .